 |
Vol.60 No.1 contents | Japanese/English |
 | Full Text of PDF (1171K) Article in Japanese |
- Case Report -
A Case of Pulmonary Adenocarcinoma with Amylase Production
Nozomi Tani1, Akihiro Yoshimura1, Sachi Harita1, Mototaka Fukui1, Tadaaki Yamada1, Koichi Takayama11Department of Respiratory Medicine, University Hospital Kyoto Prefectural University of Medicine, Japan
Background. Amylase-producing lung cancer is resistant to treatment, and serum and urinary amylase (AMY) levels have been reported to reflect the disease state and to be an indicator of treatment efficacy. Case. A man in his 60s visited our hospital due to bloody sputum and an abnormal shadow on chest computed tomography (CT). Chest CT and positron emission tomography-CT showed a consolidation in the right upper lesion, and serum AMY levels were elevated, with the salivary-type enzyme dominating. Based on findings of bronchoscopy and systemic screening, he was diagnosed with advanced AMY-producing pulmonary adenocarcinoma. We performed first-line chemotherapy using cisplatin and pemetrexed. His serum and urinary AMY levels rapidly decreased with a good partial response to chemotherapy. Conclusion. Serum and urinary AMY levels might be useful novel predictive markers in patients with AMY-producing pulmonary adenocarcinoma.
key words: Amylase-producing pulmonary adenocarcinoma, Biomarkers, Serum amylase levels, Urine amylase levels, Pemetrexed
Received: July 1, 2019
Accepted: November 7, 2019
JJLC 60 (1): 48-53, 2020
